Elekta sees several opportunities for continued strong growth

Press Release
Stockholm, Sweden, June 19, 2012

By addressing market demands, Elekta continues to offer the best products and
solutions for treating patients while increasing its market share.

At today’s Capital Markets Day in Stockholm, Sweden, Tomas Puusepp, Elekta’s
President and CEO, said that the company’s strengthened position in global
radiotherapy, will enable more people to receive cancer treatment. To achieve
this, the company will focus on its leadership in cancer care with linear
accelerators (linacs), driving stereotactic radiosurgery with Leksell Gamma
Knife® and realizing the full potential of Elekta’s software.

“Elekta has the leading linear accelerator product portfolio on the market. We
launched our revolutionary beam-shaping system, Agility*, in Europe in April and
received 510(k) clearance in the U.S. last week,” Puusepp said. “The system will
enable patients and clinics in these markets to benefit from the speed and
reliability of this innovative system and we are already experiencing strong
interest from our customers. Use of Leksell Gamma Knife® continues to expand,
and we will maintain our leadership in stereotactic radiosurgery (SRS),
including treatment of metastatic tumors. Market data in US indicate that
treatments of metastatic tumors has had a compound annual growth rate of 11**
percent from 2004 to 2010.”

He also spoke of the recent announcement by a major competitor to exit the
linear accelerator market, and expects this will further improve Elekta’s growth
opportunities. Elekta estimates this opportunity to be in excess of SEK 500
million in annual revenues for Elekta in the coming 2-3 years.

Puusepp said that Elekta’s ambition with its strategic roadmap is to increase
net sales by more than 50*** percent between 2011/12 and 2014/15.

Håkan Bergström, CFO at Elekta, explained the importance of Elekta’s installed
base of linacs. “We have seen our installed base grow by 8 percent annually,
which creates opportunities for aftermarket revenue, such as services, hardware
and software upgrades. A large installed base also leads to a growing
replacement market. The aim is to increase aftermarket revenue to about 50
percent of net sales.”

Jay Hoey, Executive Vice President Region North America, spoke about his region,
where the US is the world’s largest market for radiation therapy. “Elekta is
currently growing faster than the market,” said Hoey and added that there is
good potential for continued solid growth. “The recent 510(k) clearance from the
US Food and Drug Administration (FDA) of Agility will add to the opportunities
in US.”

Elekta has seen mixed results in Region Europe & AFLAME with strong growth in
Latin America and Northern Europe, but a slower development in Southern Europe.
The acquisition of Radon Ltda., the leading linear accelerator service company
in Brazil, will significantly strengthen Elekta’s market position. Most of the
service contracts held by Radon are with clinics that use equipment delivered by
Siemens. Through the acquisition, Elekta’s customer base increased with 25
percent in Brazil.

Gilbert Wai, Executive Vice President Asia Pacific, spoke of his region’s strong
growth of

14 percent (excluding Nucletron) in the fiscal year 2011/12. China alone has
become Elekta’s third largest market in terms of net sales, while in India,
Elekta has the highest linac sales of all vendors. Wai said that to support its
continued growth in the region, Elekta will among other things focus on training
and education.

The Capital Markets Day was held on June 19 from 13:00 CET, at the Grand Hotel
in Stockholm. A webcast from the event is available on Elekta’s website
(www.elekta.com).

*Agility is not licensed for sale in all markets. Please contact your local
representative for details.
** IMV, 2011.
*** In SEK, with current exchange rates.

###



For further information, please contact:
Håkan Bergström, CFO, Elekta AB (publ)
+46 8 587 25 547, hakan.bergstrom@elekta.com

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, e-mail: stina.thorman@elekta.com

Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 13:00 CET on June 19, 2012.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,300 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.